Association of Pulsus Paradoxus With Obesity in Normal Volunteers  by Lee, Joseph C. et al.
2. Hong K, Piper DR, Diaz-Valdecantos A, et al. De novo KCNQ1
mutation responsible for atrial fibrillation and short QT syndrome in
utero. Cardiovasc Res 2005;68:433–40.
3. Schimpf R, Wolpert C, Gaita F, Giustetto C, Borggrefe M. Short QT
syndrome. Cardiovasc Res 2005;67:357–66.
4. Levy S. Epidemiology and classification of atrial fibrillation. J Cardio-
vasc Electrophysiol 1998;9 Suppl 8:S78–82.
5. Jost N, Virag L, Bitay M, et al. Restricting excessive cardiac action
potential and QT prolongation: a vital role for IKs in human ventricular
muscle. Circulation 2005;112:1392–9.
6. Wang Z, Fermini B, Nattel S. Rapid and slow components of delayed
rectifier current in human atrial myocytes. Cardiovasc Res
1994;28:1540–6.
Association of Pulsus Paradoxus With Obesity in Normal Volunteers
To the Editor: First termed by Adolf Kussmaul in an 1873
manuscript (1), the physical finding of pulsus paradoxus (PP) has
been described in numerous clinical situations, including constric-
tive pericarditis, cardiac tamponade, acute pulmonary hyperten-
sion, severe asthma, tension pneumothorax, and exacerbations of
chronic obstructive pulmonary disease (2). Originally described as
the disappearance of the palpated pulse during inspiration in the
setting of pericardial constriction, PP has more recently been
defined as a drop in systolic blood pressure (SBP) of 10 mm Hg
with inspiration. This classic physical finding is discussed at all
levels of medical training and is frequently used in clinical
medicine.
Obesity, defined as a body mass index (BMI) 30 kg/m2, is a
condition affecting over 30% of the U.S. population and is a global
epidemic (3). In obese patients, the compressive effects of increased
abdominal girth on the chest wall and diaphragm might increase
the work of breathing. We hypothesized that this exaggerated
respiratory effort might lead to PP in otherwise healthy obese
patients. Accordingly, we performed a prospective study to inves-
tigate the relationship between obesity and PP in patients under-
going elective cardiac catheterization.
Adult patients presenting for elective cardiac catheterization
were prospectively studied for the presence of PP. These were
patients with no known or suspected pericardial or pulmonary
diseases by complete history and chart review. Inclusion criteria
were: adult patients undergoing elective cardiac catheterization
who consented to participate in the study. Exclusion criteria were:
1) any known cause of PP, to include history of chronic obstructive
pulmonary disease, active or chronic pericardial diseases, active
asthma exacerbation, or use of any bronchodilating medications;
2) urgent need for catheterization (e.g., ST-segment elevation
myocardial infarction or hemodynamic instability); 3) right ven-
tricular infarction; 4) recent pulmonary embolism; 5) pregnancy; or
6) decompensated heart failure.
On the day of cardiac catheterization, a physical examination
was performed to exclude the presence of pulmonary or pericardial
disease. Height, weight, and body circumferences at the umbilical
and xiphoid levels were measured. A limited two-dimensional
transthoracic echocardiogram was performed to exclude occult
pericardial effusion and to assess for structural changes consistent
with constrictive pericardial disease. No patient was noted to have
occult pericardial effusion or significant structural enlargement of
the heart chambers. Pulsus paradoxus was first measured non-
invasively with sphygmomanometry and then invasively assessed
within 1 h at the time of cardiac catheterization. By convention, a
PP value of 10 mm Hg was considered abnormal.
Table 1. Demographic Characteristics of the 101 Study Participants
Non-Obese
(n  64)
Obese
(n  37) p Value
Age (yrs) 58  12 57  13 0.69
Gender, male (%) 52 (81.3%) 26 (70.3%) 0.23
Smoking history, n (%)
Active 14 (23%) 9 (25%) 0.68
Prior 24 (39.3%) 11 (30.6%)
None 23 (37.7%) 16 (44.4%)
Coronary disease, n (%)
None 26 (40.6%) 20 (54%) 0.107
1-vessel 8 (12.5%) 8 (21.6%)
2-vessel 16 (25%) 3 (8.1%)
3-vessel 14 (21.9%) 6 (16.2%)
Blood pressure (mm Hg)
Systolic 144.6  23.3 142.9  20.5 0.72
Diastolic 77.5  10.5 78.4  9.6 0.65
Mean 104.2  12.9 104.5  11.7 0.91
Left ventricular end-diastolic pressure
(mm Hg), n  59
18.1  4.4 (n  35) 20.2  5.1 (n  24) 0.10
Pulse pressure (mm Hg) 67.1  23.1 64.5  18.9 0.56
Height (cm) 175.2  4.1 173.9  5.6 0.54
Weight (kg) 81.8  5.7 105.0  8.0 0.001
BMI (kg/m2) 26.6  1.4 34.7  2.2 0.001
Girth, umbilical (cm) 103.6  4.8 122.2  6.1 0.001
Girth, xiphoid (cm) 101.8  8.9 113.5  9.4 0.001
Values displayed as mean  standard deviation.
BMI  body mass index.
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With a manual sphygmomanometer, repeated measurements of
PP were taken in the supine position during normal resting tidal
respirations until a single consistent value was determined. Invasive
arterial pressure recordings were obtained via a standard coronary
arteriographic catheter placed in the ascending aorta, recording for
5 to 10 respiratory cycles at 6.25 mm/s paper speed during normal
resting tidal respirations. The change in SBP from inspiration to
expiration was manually measured by an investigator unaware of
the patients’ BMI. An average of the SBP change over a minimum
of five respiratory cycles was recorded as the PP value for each
patient. All study patients were in a regular rhythm.
The prespecified primary analysis was the prevalence of an
abnormal PP value, defined as 10 mm Hg in the obese (BMI
30 kg/m2) versus the non-obese (BMI 30 kg/m2) study
patients. Assuming a prevalence of obesity of 50% and a 5%
prevalence of PP in non-obese subjects, the study of 100 patients
was powered to detect a 20% difference in the prevalence of an
abnormal PP between the obese and non-obese groups. The t test
for independent groups was used for continuous variables, the
chi-square test was used for comparison of categorical variables,
and the Fisher exact test was used to evaluate the differences in
gender between the two groups. Bivariate correlations between
invasive PP values and abdominal girth (xiphoid and umbilical),
body surface area, and BMI were performed with the Pearson
correlation coefficient. Multivariate analysis was performed by
multivariate linear regression.
Table 1 demonstrates the characteristics and results for the
obese and non-obese patients. The prevalence of an abnormal PP
value (10 mm Hg) was significantly higher in obese compared
with non-obese patients (Fig. 1A). Measured invasively, 46% of
obese patients had PP versus 20% of non-obese patients (p 
0.012, odds ratio [OR] 3.3, 95% confidence interval [CI] 1.4 to
8.1). Measured non-invasively, 20% of the obese patients had PP
versus 1.6% of the non-obese patients (p  0.013, OR 15.5, 95%
CI 1.8 to 132.0). With an alternate invasive criterion for PP
defined as a 9% inspiratory drop in SBP (4), obesity was signifi-
cantly associated with PP (OR 5.9, 95% CI 2.0 to 17.7, p 
0.002). The mean PP value was higher in the obese versus
non-obese subjects with either invasive (10.1  2.1 vs. 7.8  1.5,
p  0.002) or non-invasive methods (7.4  3.6 vs. 5.1  2.1, p 
0.001) (Fig. 1B). The PP values were significantly correlated with
BMI (r  0.28, p  0.005), abdominal girth at the umbilical level
(r  0.33, p  0.001), and xiphoid level (r  0.27, p  0.006). In
multivariate analysis, umbilical girth was the strongest predictor of
an elevated PP value.
Our study finds that the classic teaching of a PP value
10 mm Hg as an indicator of a pericardial or pulmonary disease
process should also include obesity as a commonly associated
finding. Other than case examples (5), this is the first study that
systematically demonstrates a relationship between obesity and the
increased prevalence of PP. This has clinical implications when
dyspneic obese patients are evaluated for pericardial or pulmonary
diseases. Failure to recognize this association might lead to misdi-
agnosis, unnecessary procedures, and additional hospital admis-
sions (e.g., the obese asthmatic patient with dyspnea and a PP
value 14).
Our study calls into question the accepted value of 10 mm Hg
as the cutoff between an abnormal and normal PP value in obese
patients. This analysis suggests that in using non-invasive sphyg-
momanometric methods, a value up to 16 mm Hg might be seen
in otherwise healthy obese patients. By invasive measurements, the
PP values exceeded 10 mmHg in almost 50% of the obese patients
and 20% of the non-obese patients. The question of PP values in
disease states has been invasively studied in patients with known
pericardial tamponade. In one of the largest series of patients with
known pericardial tamponade, Reddy and Curtiss (4) proposed
different criteria for PP consisting of an absolute inspiratory
change of 12 mm Hg or 9% inspiratory drop in SBP. Applying
these invasive criteria to our population without pericardial tam-
ponade, we also found them to demonstrate an association be-
tween PP and obesity.
In summary, this study has shown that, with non-invasive or
invasive assessment, an “abnormal” PP value is seen in a substantial
proportion of individuals with a BMI exceeding 30 kg/m2. Increasing
abdominal girth also correlates with elevation in PP values. This
might also impact the use of Doppler mitral inflow and other
echocardiographic parameters of pericardial disease assessment in
Figure 1. (A) Prevalence of pulsus paradoxus (PP) by body mass index
(BMI) class. p  0.013 comparing BMI 30 with 30 kg/m2 (non-
invasive method, gray bars); p  0.019 comparing BMI 30 with 30
kg/m2 (invasive method, white bars). (B) Invasive and non-invasive PP
values in non-obese and obese patients.
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obesity. Higher thresholds are needed to avoid false positive diagnoses
in obese patients with suspected pulmonary or pericardial diseases.
Further study involving diseased and healthy obese populations is
needed to fully define the optimal diagnostic values for an
abnormal PP.
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Diabetes Lowers Six-Minute Walk Test Performance in Heart Failure
To the Editor: Tibb et al. (1) have recently observed that patients
with diabetes mellitus and left ventricular systolic dysfunction
(LVSD) have a lower peak oxygen uptake p˙VO2 than patients with
LVSD alone. Peak oxygen uptake provides important information
on risk stratification and can be used to guide management (2).
However, tests involve cycling- or walking-based protocols of
increasing speed, gradient, or resistance, are not well tolerated in
some patients with LVSD. Equipment for measuring metabolic
gas exchange is expensive and cumbersome, and availability of
trained staff is limited. The six-minute walk test (6-MWT) is an
alternative and widely used method of assessing functional capac-
ity; it is simple and cost effective to perform, it is safe because
patients are self-paced during exertion, and previous reports
suggest it is a reliable test provided it is well standardized in
patients with heart failure (3). However, to our knowledge the
impact of diabetes mellitus on 6-MWT performance has not been
investigated previously.
Patients were recruited from a local community heart failure
clinic; inclusion criteria were: stable medical therapy and evidence
of LVSD, defined as a left ventricular ejection fraction (LVEF) of
40%. Exclusion criteria were: inability to walk without assistance
from another person (not including mobility aids), chronic ob-
structive pulmonary disease (COPD) of at least moderate severity
(1-s forced expiratory volume 70% of predicted, exertional
angina, systolic blood pressure 160 mm Hg or diastolic blood
pressure 90 mm Hg, participation in an exercise training program,
and active tobacco use. Severe renal dysfunction was defined as an
estimated glomerular filtration rate of 30 ml·min·1.73 m2). The
Hull and East Riding Ethics Committee approved the study, and
all patients provided informed consent for participation. Patients
who met the inclusion/exclusion criteria underwent clinical history
and physical examination, together with electrocardiogram, echo-
cardiogram, and routine blood samples. Glycosylated hemoglobin
was measured in all patients. The 6-MWT was conducted following
a standardized protocol after usual medication (4). A flat obstacle-
free corridor, with chairs placed at either end, was used. Patients
were instructed to walk as far as possible, turning 180° every 15 m
in the allotted time.
The 6-MWT performance was compared in diabetics and
nondiabetics using the independent-samples t test. To explore the
relation between 6-MWT and potential predictor variables, can-
didate variables were assessed using univariate and multivariable
regression. For the final statistical model, the goodness-of-fit was
assessed by calculating the explained variance and by plotting the
residuals. A multivariable building process was used to identify the
“best set” of predictor variables using routinely collected data,
including diabetic state, hemoglobin, N-terminal portion of pro-
brain natriuretic peptide (NT-proBNP), hypertension, ischemic
heart disease (IHD), severe renal impairment, atrial fibrillation
(AF), LVEF, and glycosylated hemoglobin.
We recruited our patients using the same process as Tibb et al.
(1). We first identified 256 patients with chronic heart failure
(CHF) and diabetes among the 756 patients with LVEF of 40%
in our clinic. We then matched these patients for age and sex to the
remaining 500 nondiabetic patients. Patients were case-matched to
the nearest single decimal place. We found age and gender
matches for 88 patients, who were selected as our patient cohort.
The 6-MWT performance was lower in diabetic (238  124 m)
than in nondiabetic patients (296  131 m) (p  0.005) (Fig. 1).
Figure 1. Six-minute walk test (6-MWT) performance in diabetic and
nondiabetic patients with left ventricular systolic dysfunction. Median,
interquartile range, and outliers are shown. *Significant difference in
6-MWT performance between diabetics and nondiabetics (p  0.005).
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